Advertisement

Incentivizing Prescription Drug Switching to Reduce Patient and Health Plan Spending: A Microsimulation Model

  • Kai Yeung
    Correspondence
    Correspondence: Kai Yeung, PharmD, PhD, Kaiser Permanente Washington Health Research Institute, Metropolitan Park East, 1730 Minor Ave, #1600, Seattle, WA 98101, USA.
    Affiliations
    Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA

    The Comparative Health Outcomes, Policy, and Economics Institute, University of Washington, Seattle, WA, USA

    Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA
    Search for articles by this author
  • Ernesto Ulloa
    Affiliations
    Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA

    Department of Biostatistics, University of Washington, Seattle, WA, USA
    Search for articles by this author
Published:October 01, 2021DOI:https://doi.org/10.1016/j.jval.2021.08.012

      Highlights

      • Most spending for prescription drugs is on branded drugs that do not have direct generic equivalents but many of these drugs do have therapeutic alternatives within class.
      • Using a microsimulation model, we demonstrate that a direct patient payment can incentivize patients to switch from a higher cost drug to a lower cost, therapeutic alternative drug, generating both patient and health plan savings.
      • Future work should integrate considerations of shared decision making, medical ethics, and treatment effect heterogeneity into these incentive programs.

      Abstract

      Objectives

      Most spending for prescription drugs is on branded drugs that do not have direct generic equivalents but many of these drugs do have therapeutic alternatives within class. We estimate the potential savings from providing patients a financial incentive to switch from a higher cost drug to a lower cost, therapeutic alternative drug.

      Methods

      We used individual state-transition microsimulations to model medication use and spending with and without financial incentives over a 12-month time horizon with a healthcare sector perspective. Costs and utilization inputs were from individuals on branded insulins or multiple sclerosis drugs enrolled in a regional mixed-model health maintenance organization. Base-case model used a one-time financial incentive of $83 and $250 offered to patients on higher cost insulin and multiple sclerosis treatments, respectively, to switch to lower cost drugs within class.

      Results

      Savings per individual offered an incentive in the insulin and multiple sclerosis classes were, respectively, $84 (95% CI $46-$122) and $2,127 (95% CI $267-$3,987). Varying the incentive size and switch probability resulted in maximum savings of $712 at elasticity of 0.2 and incentive size $250 for the insulin drug class. For the multiple sclerosis drug class, maximum savings of $5945 was at elasticity of 0.2 and incentive size of $1000. Short time horizon makes our savings estimates conservative.

      Conclusions

      If programs such as financial incentives could encourage even a small proportion of patients to switch among drugs within therapeutic class, then substantial savings could be generated.

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Value in Health
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Papanicolas I.
        • Woskie L.R.
        • Jha A.K.
        Health care spending in the United States and other high-income countries [published correction appears in JAMA. 2018;319(17):1824].
        JAMA. 2018; 319: 1024-1039
        • Choudhry N.K.
        • Denberg T.D.
        • Qaseem A.
        • Clinical Guidelines Committee of American College of P
        Improving adherence to therapy and clinical outcomes while containing costs: opportunities from the greater use of generic medications: best practice advice from the clinical guidelines Committee of the American College of Physicians.
        Ann Intern Med. 2016; 164: 41-49
        • Dicken J.E.
        Drug pricing: research on savings from generic drug use. United States Government Accountability Office.
        (Accessed July 15, 2021)
      1. The case for competition: 2019 generic drug and biosimilars access & savings in the U.S. report. Association for Accessible Medicines.
        (Accessed July 15, 2021)
        • Shrank W.H.
        • Hoang T.
        • Ettner S.L.
        • et al.
        The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions.
        Arch Intern Med. 2006; 166: 332-337
      2. Data point: savings available under full generic substitution of multiple source brand drugs in Medicare Part D. US Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation.
        • Johansen M.E.
        • Richardson C.
        Estimation of potential savings through therapeutic substitution.
        JAMA Intern Med. 2016; 176: 769-775
      3. Medicine use and spending in the U.S. – A review of 2018 and outlook to 2023. IQVIA Institute for Human Data Science.
        (Accessed July 15, 2021)
        • Rader R.A.
        An analysis of the US biosimilars development pipeline and likely market evolution.
        BioProcess Int. 2013; 11: 16-23
        • Kang H.
        • Lobo J.M.
        • Kim S.
        • Sohn M.W.
        Cost-related medication non-adherence among U.S. adults with diabetes.
        Diabetes Res Clin Pract. 2018; 143: 24-33
        • Karter A.J.
        • Parker M.M.
        • Solomon M.D.
        • et al.
        Effect of out-of-pocket cost on medication initiation, adherence, and persistence among patients with type 2 diabetes: the Diabetes Study of Northern California (DISTANCE).
        Health Serv Res. 2018; 53: 1227-1247
        • Tamblyn R.
        • Laprise R.
        • Hanley J.A.
        • et al.
        Adverse events associated with prescription drug cost-sharing among poor and elderly persons.
        JAMA. 2001; 285: 421-429
        • Zafar S.Y.
        • Peppercorn J.M.
        • Schrag D.
        • et al.
        The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience.
        Oncologist. 2013; 18: 381-390
        • Lentz R.
        • Benson 3rd, A.B.
        • Kircher S.
        Financial toxicity in cancer care: prevalence, causes, consequences, and reduction strategies.
        J Surg Oncol. 2019; 120: 85-92
        • Havranek E.P.
        • Mujahid M.S.
        • Barr D.A.
        • et al.
        Social determinants of risk and outcomes for cardiovascular disease: a scientific statement from the American Heart Association.
        Circulation. 2015; 132: 873-898
        • Institute of Medicine
        (US) Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care.
        National Academies Press (US), Washington, DC2003
        • Dafny L.
        • Ody C.
        • Schmitt M.
        When discounts raise costs: the effect of copay coupons on generic utilization.
        Am Econ J Econ Policy. 2017; 9: 91-123
        • Mitchell M.S.
        • Goodman J.M.
        • Alter D.A.
        • et al.
        Financial incentives for exercise adherence in adults: systematic review and meta-analysis.
        Am J Prev Med. 2013; 45: 658-667
        • John L.K.
        • Loewenstein G.
        • Troxel A.B.
        • Norton L.
        • Fassbender J.E.
        • Volpp K.G.
        Financial incentives for extended weight loss: a randomized, controlled trial.
        J Gen Intern Med. 2011; 26: 621-626
        • Giuffrida A.
        • Torgerson D.J.
        Should we pay the patient? Review of financial incentives to enhance patient compliance.
        BMJ. 1997; 315: 703-707
        • DeFulio A.
        • Silverman K.
        The use of incentives to reinforce medication adherence.
        Prev Med. 2012; 55: S86-S94
        • Mantzari E.
        • Vogt F.
        • Shemilt I.
        • Wei Y.
        • Higgins J.P.
        • Marteau T.M.
        Personal financial incentives for changing habitual health-related behaviors: a systematic review and meta-analysis.
        Prev Med. 2015; 75: 75-85
      4. Smartshopper.
        https://www.smartshopper.com/
        Date accessed: March 10, 2021
        • Inserro A.
        Cigna dangles $500 to persuade patients to switch psoriasis drugs.
        AJMC. March 27, 2021;
      5. Medicine spending and affordability in the U.S. Understanding patients’ costs for medicines. IQVIA Institute for Human Data Science.
      6. Fast facts: data and statistics about diabetes. American Diabetes Association.
        • Yeung K.
        • Barthold D.
        • Dusetzina S.B.
        • Basu A.
        Patient and plan spending after state specialty-drug out-of-pocket spending caps.
        N Engl J Med. 2020; 383: 558-566
        • Krijkamp E.M.
        • Alarid-Escudero F.
        • Enns E.A.
        • Jalal H.J.
        • Hunink M.M.
        • Pechlivanoglou P.
        Microsimulation modeling for health decision sciences using R: a tutorial.
        Med Decis Making. 2018; 38: 400-422
        • Hernandez I.
        • San-Juan-Rodriguez A.
        • Good C.B.
        • Gellad W.F.
        Changes list prices net prices discounts branded drugs in the US, 2007-2018.
        JAMA. 2020; 323: 854-862
        • Lipska K.J.
        • Parker M.M.
        • Moffet H.H.
        • Huang E.S.
        • Karter A.J.
        Association of initiation of basal insulin analogs vs neutral protamine Hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with Type 2 diabetes.
        JAMA. 2018; 320: 53-62
        • Luo J.
        • Khan N.F.
        • Manetti T.
        • et al.
        Implementation of a health plan Program for Switching From Analogue to Human Insulin and Glycemic Control Among Medicare Beneficiaries With Type 2 diabetes.
        JAMA. 2019; 321: 374-384
        • Langer-Gould A.
        • Klocke S.
        • Beaber B.
        • et al.
        Improving quality, affordability, and equity of multiple sclerosis care.
        Ann Clin Transl Neurol. 2021; 8: 980-991
        • Einav L.
        • Finkelstein A.
        • Polyakova M.
        Private provision of social insurance: drug-specific price elasticities and cost sharing in Medicare Part D.
        Am Econ J Econ Policy. 2018; 10: 122-153
        • Goldman D.P.
        • Joyce G.F.
        • Lawless G.
        • Crown W.H.
        • Willey V.
        Benefit design and specialty drug use.
        Health Aff (Millwood). 2006; 25: 1319-1331
        • Manning W.G.
        • Newhouse J.P.
        • Duan N.
        • Keeler E.B.
        • Leibowitz A.
        • Marquis M.S.
        Health insurance and the demand for medical care: evidence from a randomized experiment.
        Am Econ Rev. 1987; 77: 251-277
        • R Core Team
        R: a language and environment for statistical computing.
        https://www.R-project.org/
        Date accessed: March 10, 2021
      7. Peterson KFF Health system tracker: out-of-pocket spending. Peterson Center on Healthcare, KFF.
        • Carroll W.A.
        • Miller G.E.
        • Hill S.C.
        Out-of-pocket spending for retail prescribed drugs by age and type of prescription drug coverage. Agency for Healthcare Research and Quality.
        (Accessed July 15, 2021)
        • Basu A.
        • Jena A.B.
        • Goldman D.P.
        • Philipson T.J.
        • Dubois R.
        Heterogeneity in action: the role of passive personalization in comparative effectiveness research.
        Health Econ. 2014; 23: 359-373
        • Chambers J.D.
        • Rane P.B.
        • Neumann P.J.
        The impact of formulary drug exclusion policies on patients and healthcare costs.
        Am J Manag Care. 2016; 22: 524-531
        • Horvath K.
        • Jeitler K.
        • Berghold A.
        • et al.
        Long-acting insulin analogues versus NPH Insulin (human isophane insulin) for type 2 diabetes mellitus.
        Cochrane Database Syst Rev. 2007; CD005613
        • Asch D.A.
        • Troxel A.B.
        • Stewart W.F.
        • et al.
        Effect of financial incentives to physicians, patients, or both on lipid levels: a randomized clinical trial.
        JAMA. 2015; 314: 1926-1935
      8. Addressing financial incentives to shop for lower-cost health care. The Council of Medical Service, American Medical Association.
        (Accessed July 15, 2021)
      9. Vol. 42. U.S.C. § 1320a–7b. U.S.A.: United States Code.

        • Sachdev G.
        • White C.
        • Bai G.
        Self-insured employers are using price transparency to improve contracting with health care providers: the Indiana experience.
        HealthAffairs. October 7, 2019;
        • Toussaint J.S.
        Why haven healthcare failed.
        Harvard Business Review. January 6, 2021;